James Halley

The ammunition maker's stock dropped this week with President Joe Biden calling for more gun control in the wake of a mass shooting in Colorado. Does it make sense to buy the stock on the dip?

This healthcare stock just got great news from the Food and Drug Administration.

With solid revenue growth, these stocks have the potential to more than triple over the next few years.

The GEO Group's share price has tumbled over the past 12 months, and it may have further to fall.

There are lots of reasons to be excited about DermTech's breakthrough diagnostic technology.

Innovative Industrial Properties, a cannabis REIT, and multiple-state cannabis operator Columbia Care are expected to have big revenue gains this year.

The cannabis company rewarded investors last year. Is there more gas left in the stock's tank?

There's been a lot of bad news lately for the Medicare insurer, but looking at the company's financials, could it still be a stock that richly rewards investors?

These three stocks have plenty of momentum and solid financials, making them great long-term investments.

Ocugen has set record highs this month on news regarding COVID-19 vaccine Covaxin. Is it too late to get in on the stock?

The pandemic puppy boom is real, and so are sales for these three pet stocks.

Green Thumb Industries, one of the biggest marijuana stocks by market cap, is finally turning a profit.

The past 12 months have been a wild ride for the genetic testing company's stock, with a sub-$10 low and a high of more than $60.

These stocks made investors a lot of money in 2020. Which one will be the better choice this year?

Both tech-related medical stocks have had a phenomenal past 12 months, with shares rising more than 90%. But only one has a solid chance to continue that level of growth in 2021.

There's no hiding that high-yield stocks can also bring high risk. These three stocks, however, offer high yields at a discount with relatively low risk.

There are plenty of stocks that will pay you a dividend each month. The trick is finding the right ones at the right time.

The biotech has a lot riding on whether the FDA approves its potential Alzheimer's treatment, aducanumab.

In a field that's becoming more crowded, what will set Editas apart?

These three dividend stocks combine steady growth with solid dividend payouts.